Atezolizumab for Bladder Cancer

"This trial is accepting participants from 8 distinguished medical sites, such as New york University Clinical Cancer Center of Memphis, West Cancer Center University of Tennessee in Milwaukee, and Froedtert & The Medical College of Wisconsin located in Phoenix. Other locations are also participating."

"Information hosted on clinicaltrials.gov discloses that this medical trial is not accepting applications at the present time, despite being initially posted in September 2017 and last updated in August 2022. Notwithstanding, there are 835 other research studies recruiting participants as we speak."

"This study has since ended recruitment. The original post was published on September 13th 2017, with the latest update occuring August 1st 2022. There are 214 and 621 clinical trials for carcinoma transitional cell and Atezolizumab respectively that are presently open to patients looking for studies to join."

"Presently, 621 clinical studies for Atezolizumab are being conducted, with 142 in Phase 3. These trials have a global distribution of 31793 sites; however the majority is based in Taibei, Taiwan."

"Due to the fact that Atezolizumab is a Phase 2 trial and thus lacks clinical data affirming its efficacy, our team at Power rates this drug's safety as a 2 on a scale of 1 to 3."

"Atezolizumab is traditionally used to treat non-small cell lung carcinoma, but also has positive effects on conditions such as postoperative recurrent non-squamous NSCLC and recurrent platinum-sensitive epithelial ovarian cancer."